Global Pulmonary arterial hypertension (PAH) Market provides a brief and detailed knowledge about key players, market state and circumstances that are covered deeply in this report. The business chain supporting the Pulmonary arterial hypertension (PAH) market is analysed in detail covering accurate information about aspects such as the industrial chain, proficiency in utilization of the available capacity of manufacture, and industry strategies that affect the market.
Pulmonary arterial
hypertension (PAH) Market study offers an exhaustive summary of the vendor
landscape, competitive analysis, and key strategies to gain ruthless advantage.
Pulmonary arterial hypertension (PAH) Market Forecast provides sizing and
growth opportunities. It provides comprehensive insights on the latest industry
trends, forecast, and growth drivers in the market. it also includes a detailed
analysis of growth drivers, challenges, and investment opportunities and
delivers a complete overview of segments and the regional outlook of the
market.
Get Free PDF Sample (Including Full TOC,
List of Tables & Figures) @ https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market/request-sample
The global pulmonary
arterial hypertension (PAH) market size was valued at USD 5.0 billion in 2015
and is anticipated to reach USD 8.7 billion by 2025. Pulmonary arterial
hypertension (PAH) is a type of high blood pressure that occurs in the right
side of the heart and in the arteries that supply blood to the lungs. These
arteries are called pulmonary arteries. PAH occurs when the pulmonary arteries
thicken or grow rigid. PAH is one of the five groups of pulmonary hypertension,
classified by the World Health Organization (WHO).
The market for PAH is
growing moderately due to newer launches of pipeline drugs that target
different pathways to suppress the symptoms of the disease. Early diagnosis of
the disease has played a pivotal role in number of patients undergoing
treatment.
Globally the PAH market is
segmented on the basis of Drug class, Surgery, and region. On the basis of Drug
class, the global PAH market is classified into Endothelin Receptor Antagonists
(ERAs) (Tracleer, Opsumit, Letairis)- These medications reverse the effect of
endothelin, a substance in the walls of blood vessels that causes them to
narrow; Prostacyclin and Prostacyclin Analogs- were the first medications
approved by the U.S. FDA for the treatment of PAH. Phosphodiesterase-5 (PDE-5)
V Inhibitors, Sildenafil, and Tadalafil- Revatio, Viagra, Cialis, etc. These
drugs work by opening the blood vessels in the lungs to allow blood to flow
easily. These drugs have superiority over existing therapy options with respect
to the therapeutic efficacy, route of administration, and side-effects.
A new drug called Uptravi
(selexipag), which is a selective IP prostacyclin receptor agonist, is expected
to be launched in 2016 and is likely to drive growth of the prostacyclin and prostacyclin
analogs market. The rising sales of these newly-approved therapeutic agents are
likely to contribute to the overall revenue of the market.
Globally, regulatory bodies
have granted an Orphan Drug Designation (ODD) status to all those drugs intended
to diagnose and treat or cure a rare disease. In the U.S., the Orphan Drug Act
(ODA) encourages pharmaceutical industries to develop orphan drugs by offering
benefits such as tax credits, research grants, and orphan drug exclusivity of
seven years. These benefits are escalating the development, manufacturing, and
marketing of drugs intended to treat PAH, thereby driving market growth.
On the basis of surgeries,
the global PAH market is classified into Atrial Septostomy- This is an open
heart surgery; in which surgeon will create an opening between the upper left
and right chambers of your heart to relieve the pressure on the right side of
heart. Transplantation- Lung or heart-lung transplant might be an option
especially for younger people who have idiopathic pulmonary arterial
hypertension.
Geographically, PAH market
is segmented into North America, Europe, Asia Pacific, Latin America, MEA, and
Rest of the World. North America held the maximum share of market for PAH in
terms of revenue in 2013, which is then followed by Europe. These two developed
regions are expected to witness substantial growth during the forecast period,
due to the recently approved PAH drugs in the market and the products that are
anticipated to receive approval during the next few years. In the Asia Pacific
region, Japan, China, India, Australia, and New Zealand exhibit immense
opportunities for the companies operating in the PAH market.
The low level of awareness
regarding the diagnosis and treatment of PAH is one of the prime reasons
restraining the market growth in MEA and rest of the world. The patent
expirations of major PAH drugs along with the availability of generic drugs are
expected to adversely affect the overall revenue of the market. Some of the
major players in the market are Actelion Pharmaceuticals, Ltd., Bayer
HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International
AG, Pfizer, Inc. and United Therapeutics Corporation are the key players
operating in the global PAH market.
Know More Insights
@ https://newsonmarketblog.wordpress.com
No comments:
Post a Comment